| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | 0.099 | 0.01 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.082 | 0.01 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.01 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.02 |
| mRNA | selumetinib:GDC-0941 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | -0.17 | 0.02 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.02 |